Cargando…

Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients

This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II multicenter, open-label clinical trial receiving lenalidomide alone or lenalidomide plus cetuximab. The main findings show the T cell immunostimulatory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gandhi, Anita K., Shi, Tao, Li, Mingyu, Jungnelius, Ulf, Romano, Alfredo, Tabernero, Josep, Siena, Salvatore, Schafer, Peter H., Chopra, Rajesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823649/ https://www.ncbi.nlm.nih.gov/pubmed/24244687 http://dx.doi.org/10.1371/journal.pone.0080437

Ejemplares similares

Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2013)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
por: Del Re, Marzia, et al.
Publicado: (2014)

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014)

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
por: Tabernero, Josep, et al.
Publicado: (2023)

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
por: Cortés-Hernández, Josefina, et al.
Publicado: (2012)

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
por: Baas, J. M., et al.
Publicado: (2015)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction
por: Tian, Sun, et al.
Publicado: (2013)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
por: Zhang, Hangyu, et al.
Publicado: (2020)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
por: Bartlett, J B, et al.
Publicado: (2005)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Cetuximab in Refractory Skin Cancer Treatment
por: Kalapurakal, Sini J, et al.
Publicado: (2012)

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
por: Nakamura, Masato, et al.
Publicado: (2016)

Platycodin D sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the PI3K/Akt signaling pathway
por: Liu, Yanfei, et al.
Publicado: (2022)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Differential effects of lenalidomide during plasma cell differentiation
por: Jourdan, Michel, et al.
Publicado: (2016)

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer
por: Tashiro, Takahiro, et al.
Publicado: (2017)

Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation
por: Chen, Peng, et al.
Publicado: (2020)

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer
por: Yang, Jiawen, et al.
Publicado: (2021)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2022)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Lenalidomide: An Alternative Treatment for Refractory Behçet’s Disease and Relapsing Polychondritis
por: Brazão, Sofia Gomes, et al.
Publicado: (2019)

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
por: Gandhi, Anita K, et al.
Publicado: (2014)

The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells
por: Kibata, Kayoko, et al.
Publicado: (2019)

Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study
por: Krens, Lisanne L., et al.
Publicado: (2014)

Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines
por: Kim, Sujin, et al.
Publicado: (2019)

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
por: Greene, Michelle K., et al.
Publicado: (2020)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t8qp2g2ca2n5lp9gl2o7otca6m